Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

FDA OKs Medtronic's Evolut TAVR New Indication For Low Risk

By Zacks Investment ResearchStock MarketsAug 20, 2019 11:00PM ET
FDA OKs Medtronic's Evolut TAVR New Indication For Low Risk
By Zacks Investment Research   |  Aug 20, 2019 11:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Medtronic plc’s (NYSE:MDT) Evolut Transcatheter Aortic Valve Replacement (TAVR) system has won the FDA’s approval for expanded indication to treat symptomatic severe native aortic stenosis in patients at a low risk of surgical mortality. This, in turn, opens the route to traditional open heart surgery’s minimally invasive alternative path for the younger patient set, who is more active than higher-risk patients. Undoubtedly, the latest indication will increase the patient base for Medtronic’s TAVR platform within its Cardiac and Vascular division.

With this nod, the Evolut TAVR platform is now indicated for symptomatic severe aortic stenosis (AS) patients across all risk categories (extreme, high, intermediate and low) in the United States.

What is Aortic Stenosis?

AS refers to a serious medical condition wherein one’s aortic valve narrows. It can cause cardiac arrest and even death, if left untreated. Aortic valve replacement is a standard procedure to treat such patients. However, those at risk of open-heart surgery can instead be treated with transcatheter heart valve (THV) implantation of a device like Evolut using a less-invasive procedure.

A Brief Note on the Evolut TAVR Approval

The expanded indication approval came on the back of a favorable clinical outcome from the global, prospective, multi-center Evolut Low Risk Trial, which evaluated three valve generations, namely CoreValve, Evolut R and Evolut PRO in more than 1,400 patients.

The data showed that TAVR has a superiorsafety profile and can be an effective treatment option in low-risk patients with shorter hospital stays. It also provides improved quality-of-life scores compared with the condition post open-heart surgical valve replacement (SAVR).

Huge Market Prospects

Per Medtronic, severe AS affects approximately 165,000 low-risk patients per year in the United States, Western Europe and Japan. It occurs when the aortic valve becomes diseased (stenotic). If left untreated, patients with severe aortic stenosis can die from heart failure barely within a couple of years. We expect this new indication to capture the market of low-risk patients effectively.

Zacks Rank and Other Key Picks

Medtronic currently carries a Zacks Rank # 2 (Buy). A few other top-ranked stocks in the broader medical space are DENTSPLY SIRONA (NASDAQ:XRAY) , Baxter (NYSE:BAX) and Abbott Laboratories (NYSE:ABT) , each holding the same top Zacks Rank as Medtronic. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.

Baxter’s long-term earnings growth rate is projected at 12.8%.

Abbott’s long-term earnings growth rate is expected to be 10.9%.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>

Abbott Laboratories (ABT): Free Stock Analysis Report

Baxter International Inc. (BAX): Free Stock Analysis Report

Medtronic PLC (MDT): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

Original post
FDA OKs Medtronic's Evolut TAVR New Indication For Low Risk

Related Articles

David Moenning
Market Is Rethinking The Outlook By David Moenning - Jan 18, 2022

From my seat, the key driver to the current action in the stock market remains the spike in bond yields. This morning's early dance to the downside represents an exclamation point...

FDA OKs Medtronic's Evolut TAVR New Indication For Low Risk

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email